Patten & Patten Inc. TN reduced its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,545 shares of the exchange traded fund’s stock after selling 175 shares during the period. Patten & Patten Inc. TN’s holdings in SPDR S&P Biotech ETF were worth $647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in the company. Baker Avenue Asset Management LP acquired a new position in shares of SPDR S&P Biotech ETF in the 3rd quarter valued at $343,000. Guerra Pan Advisors LLC raised its position in SPDR S&P Biotech ETF by 6.6% during the third quarter. Guerra Pan Advisors LLC now owns 7,752 shares of the exchange traded fund’s stock worth $766,000 after acquiring an additional 480 shares during the period. Sigma Planning Corp raised its position in SPDR S&P Biotech ETF by 46.4% during the third quarter. Sigma Planning Corp now owns 11,924 shares of the exchange traded fund’s stock worth $1,178,000 after acquiring an additional 3,781 shares during the period. Atria Investments Inc raised its position in SPDR S&P Biotech ETF by 2.1% during the third quarter. Atria Investments Inc now owns 9,016 shares of the exchange traded fund’s stock worth $891,000 after acquiring an additional 188 shares during the period. Finally, Essex Savings Bank acquired a new position in SPDR S&P Biotech ETF during the third quarter worth $236,000.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA:XBI opened at $103.50 on Tuesday. The company has a fifty day moving average of $99.00 and a two-hundred day moving average of $95.83. The stock has a market capitalization of $7.89 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a fifty-two week low of $64.99 and a fifty-two week high of $105.47.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- The Risks of Owning Bonds
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Canadian Penny Stocks: Can They Make You Rich?
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.